BLOG

How NK Cell Therapy Enhances Antibody Drugs via ADCC

7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

In modern cancer care, combining different therapies is a key strategy for improving outcomes. One area of growing interest is the synergy between antibody drugs and cell-based immunotherapies. This article explores how NK (Natural Killer) cell therapy may enhance the effectiveness of certain antibody drugs through a powerful immune mechanism known as Antibody-Dependent Cellular Cytotoxicity (ADCC).

Understanding Antibody-Dependent Cellular Cytotoxicity (ADCC)

To understand the potential synergy, we first need to look at the two components involved: antibody drugs and NK cells. Many modern cancer treatments use monoclonal antibodies, which are lab-engineered proteins designed to recognize and attach to specific targets (antigens) on the surface of cancer cells. Drugs like rituximab, trastuzumab, and cetuximab work in part by “marking” these malignant cells for destruction by the immune system.

This is where NK cells play a crucial role. NK cells are a type of white blood cell and a cornerstone of our innate immune system. As their name suggests, they are “natural killers” that can identify and attack abnormal cells, such as cancer cells, without prior sensitization. One of their most important functions is ADCC. When an antibody drug binds to a cancer cell, its “tail” (the Fc region) acts as a flag. NK cells have receptors (CD16) that recognize this flag, allowing them to latch onto the antibody-coated cancer cell. This binding activates the NK cell, which then releases cytotoxic granules containing proteins like perforin and granzymes, leading to the destruction of the targeted cancer cell.

The Role of NK Cell Therapy in Potentiating ADCC

The effectiveness of ADCC is highly dependent on having a sufficient number of healthy, active NK cells. However, the progression of cancer and the side effects of conventional treatments like chemotherapy can weaken a patient’s immune system, leading to a decline in both the quantity and activity of NK cells. When the NK cell population is compromised, the ability of antibody drugs to trigger a robust ADCC response may be limited.

NK cell therapy is a type of immunotherapy that aims to address this issue directly. The process involves collecting a sample of the patient’s own blood, from which NK cells are isolated. These cells are then activated and expanded in number in a specialized cell processing facility over several weeks. Finally, this larger, more active population of the patient’s own NK cells is returned to the body through an intravenous (IV) infusion.

By increasing the number of potent NK cells circulating in the body, this therapy is expected to provide a larger pool of effector cells capable of participating in ADCC. A greater number of active NK cells could potentially lead to a more powerful and efficient elimination of cancer cells marked by antibody drugs, thereby enhancing the overall therapeutic effect of the combination treatment.

Who Might Consider This Combination Approach?

This combination approach may be a consideration for individuals who are undergoing treatment with antibody drugs and wish to explore options to support their immune function. It is important to understand that NK cell therapy is not a replacement for standard cancer treatments such as surgery, chemotherapy, or radiation therapy. Instead, it is considered a complementary therapy that can be used alongside them.

Patients often explore this therapy with goals such as supporting their body’s natural defenses during intensive treatment or as part of a plan to manage the risk of recurrence after primary treatment is complete. The decision to pursue any treatment, including a combination approach, is highly personal and depends on many factors, including the type and stage of cancer, overall health, and the specifics of the current treatment plan. A thorough discussion with a physician is essential to determine if this approach is suitable for your individual situation.

Important Considerations Before Your Consultation

If you are considering NK cell therapy, it is vital to have accurate information. Here are some key points to keep in mind for your discussion with a medical professional:

  • Regulatory Framework: In Japan, advanced cell therapies like this are provided under the Act on the Safety of Regenerative Medicine. This ensures that treatments are conducted according to plans reviewed by certified committees and reported to the Ministry of Health, Labour and Welfare.
  • Nature of Treatment: This therapy uses your own (autologous) cells, which generally minimizes the risk of rejection or severe side effects. However, some patients may experience temporary, mild side effects like fever or fatigue after the infusion.
  • Uninsured Medical Care: NK cell therapy is an elective treatment and is not covered by Japanese public health insurance. Patients are responsible for the full cost of the treatment.
  • Individual Assessment is Crucial: The suitability, potential benefits, risks, and expected outcomes of this therapy can only be determined after a comprehensive medical evaluation by a doctor. Treatment effects and responses vary from person to person, and no outcome can be guaranteed.

Learn More at Grand Green Osaka Umekita Clinic

Understanding all available options is a critical part of managing your health. If you are in the Osaka area and wish to learn more about cancer immunotherapy, the team at Grand Green Osaka Umekita Clinic is available for consultations. We provide information and care for both local and international patients, with resources available in multiple languages.

A medical consultation is the necessary first step to explore whether NK cell therapy, alone or in combination with other treatments, is an appropriate option for you. For a detailed overview of the treatment process, features, and frequently asked questions, please see our NK Cell Therapy page.

In summary, the ADCC mechanism provides a clear biological rationale for combining NK cell therapy with antibody drugs. By reinforcing the body’s own population of NK cells, this approach aims to unlock the full potential of antibody-based treatments. As with any medical treatment, a thorough consultation with a qualified physician is essential to make an informed decision based on your unique health circumstances.

Learn more about NK Cell Therapy

References

Supervising Physician

Hidenori Shimada

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to NK Cell Therapy ›

Grand Green Osaka South Building, Gate Tower 5F 5-54 Ofuka-cho, Kita-ku, Osaka 530-0011, Japan

TEL: 06-7653-8493 FAX: 06-7635-8052

Contact